Last reviewed · How we verify
NCT06178003
the Safety and Efficacy of Intravitreal Injection of Tpdelansbsalbac in Malignant Effusions.
NA trial testing Tpdelansbsalbac in Salmonella Bacteremia in 65 participants. Status unknown.
1 April 2024
Quick facts
| Lead sponsor | The First Affiliated Hospital of Xinxiang Medical College |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 65 |
| Start date | 11 February 2024 |
| Primary completion | 1 April 2024 |
| Estimated completion | 1 January 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tpdelansbsalbac — full drug profile →
Conditions studied
- Salmonella Bacteremia — all drugs for Salmonella Bacteremia →
Sponsor
The First Affiliated Hospital of Xinxiang Medical College
Who can join
18 and older, any sex, with Salmonella Bacteremia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase I/II, open, first-in-human (FIH) study of Transebacillus in Patients with malignant pleural and abdominal effusions. It consists of Phase Ia to determine the Maximum tolerated dose (MTD) or Recommended Phase 2 dose (RP2D) of Transebacillus, and Phase Ib/II to explore and confirm the efficacy, safety and Tolerability.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Analysis of intratumoural bacteria: Opportunities and challenges for cancer therapy.
Jiang X, Zhang C, Cao S, Peng Y, et al · · 2026 · PMID 42180532 · DOI 10.1016/j.apsb.2026.03.022 -
Engineering Salmonella as an immune-metabolic modulator of the tumor microenvironment.
Varsha KK, Dwidar M. · · 2026 · PMID 41820175 · DOI 10.1016/j.tibtech.2026.01.010
Verify or expand the search:
- PubMed search for NCT06178003
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The First Affiliated Hospital of Xinxiang Medical College trials
Trials by the same sponsor.
- NCT07530016 — Clinical Efficacy and Mechanisms of a Topical Azone-Tranexamic Acid-Aloe Polysaccharide Gel in the Treatment of Melasma · NA · not yet recruiting
- NCT07530003 — HUMSCs Combined With Col I to Third-Degree Burn Wound · Phase 1, PHASE2 · recruiting
- NCT07347496 — A Randomized, Controlled Clinical Trial Comparing Remimazolam Besylate Combined With Alfentanil Versus Propofol Combined · Phase 4 · not yet recruiting
- NCT07476534 — Exploration Study of Molecular Biomarkers for Tumor-related Anxiety and Depression · not yet recruiting
- NCT07376577 — Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing ERCP · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06178003 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xinxiang Medical College
- Last refreshed: 29 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06178003.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing